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We would like to add some comments to the paper
“Detection of carbapenemases in Enterobacteriaceae: a chal-
lenge for diagnostic microbiological laboratories” by Hrabak J
et al., which provides an exhaustive review of the state of the
art in laboratory detection of carbapenemase-producing
Enterobacteriaceae (CPE), including carbapenemase-producing
Klebsiella pneumoniae (CPKP) [1].
As recognized by the authors, the uncontrolled in-hospital
and community spread due to undetected carriers is one of
the key factors responsible for CPE diffusion in endemic areas.
Therefore, the use of rapid diagnostic methods may be critical
to identify these carriers, for both epidemiological and
contention purposes. However, the use of innovative diag-
nostic tools may not be useful without identifying at risk
subjects to be screened. Under this light, our experience about
CPKP bloodstream infections (BSI) seems to suggest an
unexpectedly high circulation of unscreened carriers.
From January 2012 to August 2014 in our hospital we
observed 182 episodes of CPKP BSI. The median time to
diagnosis from hospital admission was 22 days (IQR 11–39).
However, 14 of these episodes occurred much earlier (i.e.,
within 48 h from hospital admission). To understand factors
associated with CPKP infections at hospital admission we
analysed the clinical characteristics of these patients. Clinical
data was retrieved using a prospectively collected database of
CPKP bacteraemia combined with charts review. The follow-
ing variables were analysed: age, gender, previous hospitaliza-
tions, time from previous hospitalizations, prior screening for
CPKP colonization, diabetes mellitus, presence of solid neo-
plasm or haematological malignancies, previous chemotherapy/
radiotherapy, neutropenia, previous surgical procedures,
chronic renal impairment, and chronic liver disease. As shown
in Table 1, all patients had been hospitalized previously within
a pretty short time frame (median 16 days, IQR 7–80). They all
had the classic risk factors for CPKP bacteraemia, like
advanced age, diabetes, cancer, and previous surgery. How-
ever, surprisingly only two of them were colonized at time of
bacteraemia.
At this point, we wondered if the lack of colonization was
due to lack of compliance with hospital screening rules (i.e.,
patients should have been screened but were not), true
negativity (patients were screened but were not colonized), or
any other reason. Quite surprisingly we found that the
majority of these patients (11/14, 79%) had not been screened
because they had been hospitalized in wards considered at low
risk for CPKP infections, in which, therefore, universal
screening was not recommended [2].
CRKP have been classically associated with prolonged
in-hospital stay [3]. However, Corcione et al. recently
described 18 patients with early onset CPKP BSI (within
5 days from hospital admission) [4]. Consistently with our
findings, only 28% of them were known to be colonized,
despite an overall high rate of previous hospitalization (72%).
Although data regarding previous screening was not provided,
a previous undetected colonization is likely to have occurred
in at least some of these cases.
This short report and the one from Corcione et al. raises
some concern about the suitability of selective screening aimed
at CPKP containment, i.e. to perform the screening only in
patients admitted to some high risk units (intensive care units
or cancer wards), and in their contacts [1,2]. If confirmed in
larger series, these observational data might be worrisome
from a public health standpoint, as an undetected carriage
TABLE 1. Characteristics of patients with early onset CPKP
BSI*





Total 14 11 (79)
Age (years)
Median (IQR) 73 (66–79) 77 (70–80)
Gender
Male 10 (71) 7 (64)
Previous hospitalization (within 6 months) 14 (100) 11 (100)
Time from previous hospitalization (days)
Median (IQR) 16 (7–80) 21 (8–105)
Prior screening for CPKP † 2 (14) 0 (0)
Diabetes 2 (14) 2 (18)
Solid neoplasm 6 (43) 5 (45)
Haematological malignancies 1 (7) 1 (9)
Previous chemotherapy/radiotherapy 2 (14) 2 (18)
Neutropenia (ANC < 500/mm3) 1 (7) 1 (9)
Previous surgical procedures
(within 3 months before BSI)
3 (21) 2 (18)
Chronic renal impairment 4 (29) 3 (27)
Chronic liver disease 0 (0) 0 (0)
CPKP, carbapenemase-producing Klebsiella pneumoniae; BSI, bloodstream infection;
ANC, absolute neutrophils count; IQR: interquartile range.
*Within 48 hours from hospital admission.
**According to guidelines [1,2]: medical wards 7/11 (64%), surgery 4/11 (36%).
†Thru rectal swab, according to local screening policies.
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involves the lack of adequate contact precautions by caregiv-
ers, physicians, relatives, and patients themselves, enhancing
the potential for both in-hospital and community CPKP
diffusion. Since only 8% among hospitalized carriers develop
invasive infections [5], many more colonized patients might be
circulating in the community, that are unaware of their status.
In conclusion, our experience suggests that a higher than
expected CPKP circulation in hospitals is possible. Surveillance
studies in low-risk wards and in the out-patient setting are
urgently needed, in order to confirm and quantify this
phenomenon. We think the development of any innovative
and rapid diagnostic tool is critical for these purposes, since
detailed and rapid epidemiological data is essential to assess
whether the extension of screening policies to low risk wards
is a cost-effective measure to contain CPKP diffusion.
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